AZD5363 HAS CLINICAL ACTIVITY IN PATIENTS WITH AKT1-MUTANT SOLID TUMORS

被引：3
|
作者：
Hyman, D. M.
Smyth, L. M.
Donoghue, M. T. A.
Westin, S. N.
Bedard, P. L.
Dean, E. J.
机构：
来源：
CANCER DISCOVERY | 2017年 / 7卷 / 07期
关键词：
D O I：
10.1158/2159-8290.CD-RW2017-093
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：662 / 662
页数：1
相关论文
共 50 条
  • [41] Two predominant molecular subtypes of spinal meningioma: thoracic NF2-mutant tumors strongly associated with female sex, and cervical AKT1-mutant tumors originating ventral to the spinal cord
    Hua, Lingyang
    Alkhatib, Majd
    Podlesek, Dino
    Guenther, Leila
    Pinzer, Thomas
    Meinhardt, Matthias
    Zeugner, Silke
    Herold, Sylvia
    Cahill, Daniel P.
    Brastianos, Priscilla K.
    Williams, Erik A.
    Clark, Victoria E.
    Shankar, Ganesh M.
    Wakimoto, Hiroaki
    Ren, Leihao
    Chen, Jiawei
    Gong, Ye
    Schackert, Gabriele
    Juratli, Tareq A.
    ACTA NEUROPATHOLOGICA, 2022, 144 (05) : 1053 - 1055
  • [42] Two predominant molecular subtypes of spinal meningioma: thoracic NF2-mutant tumors strongly associated with female sex, and cervical AKT1-mutant tumors originating ventral to the spinal cord
    Lingyang Hua
    Majd Alkhatib
    Dino Podlesek
    Leila Günther
    Thomas Pinzer
    Matthias Meinhardt
    Silke Zeugner
    Sylvia Herold
    Daniel P. Cahill
    Priscilla K. Brastianos
    Erik A. Williams
    Victoria E. Clark
    Ganesh M. Shankar
    Hiroaki Wakimoto
    Leihao Ren
    Jiawei Chen
    Ye Gong
    Gabriele Schackert
    Tareq A. Juratli
    Acta Neuropathologica, 2022, 144 : 1053 - 1055
  • [43] Longitudinal patient-reported outcomes (PROs) and qualitative assessment of symptom burden within a phase 1b trial of a PARP inhibitor olaparib combined with an oral mTORC1/2 inhibitor (AZD2014) or an AKT inhibitor (AZD5363)
    Meyer, Larissa A.
    Sun, Charlotte
    Shi, Qiuling
    Westin, Shannon
    Haq, Shireen
    Savelieva, Katerina
    Coleman, Robert
    Mills, Gordon
    Williams, Loretta
    QUALITY OF LIFE RESEARCH, 2018, 27 : S77 - S77
  • [44] Clinical and molecular features of PTCH1 mutant in solid tumors
    Li, X.
    Han, T.
    Guo, D.
    Kong, R.
    Chen, S.
    Ding, R.
    Deng, W.
    Bu, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S268 - S269
  • [45] 2-Deoxy-2-[18F]fluoro-d-glucose Positron Emission Tomography Demonstrates Target Inhibition with the Potential to Predict Anti-Tumour Activity Following Treatment with the AKT Inhibitor AZD5363
    Juliana Maynard
    Sally-Ann Ricketts
    Christelle Gendrin
    Phillippa Dudley
    Barry R Davies
    Molecular Imaging and Biology, 2013, 15 : 476 - 485
  • [46] 2-Deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography Demonstrates Target Inhibition with the Potential to Predict Anti-Tumour Activity Following Treatment with the AKT Inhibitor AZD5363
    Maynard, Juliana
    Ricketts, Sally-Ann
    Gendrin, Christelle
    Dudley, Phillippa
    Davies, Barry R.
    MOLECULAR IMAGING AND BIOLOGY, 2013, 15 (04) : 476 - 485
  • [47] "BEECH", a phase I/II study of the AKT inhibitor AZD5363 combined with paclitaxel in patients with advanced or metastatic breast cancer: results from the dose-finding study, including quantitative assessment of circulating tumor DNA as a s
    Turner, Nicholas C.
    Oliveira, Mafalda
    Armstrong, Anne
    Sablin, Marie-Paule
    Perez-Fidalgo, Jose A.
    Herebien, Sarah
    Garcia-Murillas, Isaac
    Johnson, Stan
    Foxley, Andrew
    Mahmood, Adnan
    Lindemann, Justin P.
    CANCER RESEARCH, 2015, 75
  • [48] BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population
    Turner, N. C.
    Alarcon, E.
    Armstrong, A. C.
    Philco, M.
    Lopez Chuken, Y. A.
    Sablin, M. -P.
    Tamura, K.
    Gomez Villanueva, A.
    Perez-Fidalgo, J. A.
    Cheung, S. Y. A.
    Corcoran, C.
    Cullberg, M.
    Davies, B. R.
    de Bruin, E. C.
    Foxley, A.
    Lindemann, J. P. O.
    Maudsley, R.
    Moschetta, M.
    Outhwaite, E.
    Pass, M.
    Rugman, P.
    Schiavon, G.
    Oliveira, M.
    ANNALS OF ONCOLOGY, 2019, 30 (05) : 774 - 780
  • [49] Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
    Fan, Bin
    Mellinghoff, Ingo K.
    Wen, Patrick Y.
    Lowery, Maeve A.
    Goyal, Lipika
    Tap, William D.
    Pandya, Shuchi S.
    Manyak, Erika
    Jiang, Liewen
    Liu, Guowen
    Nimkar, Tara
    Gliser, Camelia
    Judge, Molly Prahl
    Agresta, Sam
    Yang, Hua
    Dai, David
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (02) : 433 - 444
  • [50] Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
    Bin Fan
    Ingo K. Mellinghoff
    Patrick Y. Wen
    Maeve A. Lowery
    Lipika Goyal
    William D. Tap
    Shuchi S. Pandya
    Erika Manyak
    Liewen Jiang
    Guowen Liu
    Tara Nimkar
    Camelia Gliser
    Molly Prahl Judge
    Sam Agresta
    Hua Yang
    David Dai
    Investigational New Drugs, 2020, 38 : 433 - 444
12345